Discontinued drugs in 2008: oncology drugs.

abstract：INTRODUCTION:Signal transducer and activator of transcription 3 (STAT3) controls a key signaling pathway in the development of many malignant diseases. Several genetic studies have proven its central role in the regulation of apoptosis, proliferation, angiogenesis and immune responses making it an attractive target for...

journal_title：Expert opinion on investigational drugs

authors： Mankan AK,Greten FR

更新日期：2011-09-01 00:00:00

abstract：:Improving the tumour selectivity of cytotoxic drugs through conjugation to tumour-reactive monoclonal antibodies may lead to novel, more potent agents for cancer therapy. The maytansinoid drugs are 100- to 1000-fold more cytotoxic in vitro than current clinical anticancer drugs. We recently demonstrated that conjugati...

journal_title：Expert opinion on investigational drugs

authors： Liu C,Chari RV

更新日期：1997-02-01 00:00:00

abstract：:Plasma concentrations of the peptide endothelin (ET) are elevated in several cardiovascular diseases. Animal studies suggest that activation of ET receptors may contribute to the increase in vascular resistance and remodelling of cardiovascular tissues that are characteristic of these pathologies. Antagonists of these...

journal_title：Expert opinion on investigational drugs

authors： Maguire JJ,Davenport AP

更新日期：1999-01-01 00:00:00

abstract：INTRODUCTION:IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in Phase I - III of clinical development for RA. A...

journal_title：Expert opinion on investigational drugs

authors： Semerano L,Thiolat A,Minichiello E,Clavel G,Bessis N,Boissier MC

更新日期：2014-07-01 00:00:00

abstract：:Introduction: The armamentarium of antileishmanial drugs is small. It is further being threatened by the development of resistance and decreasing sensitivity to the available drugs. The development of newer drugs is sorely needed. Areas covered: The authors have based their review on a literature search performed usin...

journal_title：Expert opinion on investigational drugs

authors： Sundar S,Chakravarty J

更新日期：2015-01-01 00:00:00

abstract：:Introduction: Cyclin-dependent kinase 7 (CDK7) is a part of the CDK-activating kinase family (CAK) which has a key role in the cell cycle and transcriptional regulation. Several lines of evidence suggest that CDK7 is a promising therapeutic target for cancer. CDK7 selective inhibitors such as SY-5609 and CT7001 are in...

journal_title：Expert opinion on investigational drugs

authors： Liang H,Du J,Elhassan RM,Hou X,Fang H

更新日期：2021-01-01 00:00:00

abstract：:When the 'handle region' of the prorenin prosegment interacts with the (pro)renin receptor, the prorenin molecule partially changes the conformation to an enzymatically active state. On the other hand, the receptor triggers its own intracellular signalling pathways independent of the renin-angiotensin system (RAS). Th...

journal_title：Expert opinion on investigational drugs

authors： Ichihara A,Kaneshiro Y,Suzuki F

更新日期：2006-10-01 00:00:00

abstract：INTRODUCTION:Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of...

journal_title：Expert opinion on investigational drugs

authors： Smith-Harrison L,Starke NR,Smith RP,Kovac JR

更新日期：2017-06-01 00:00:00

abstract：:This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in...

journal_title：Expert opinion on investigational drugs

authors： Kelland LR

更新日期：2000-12-01 00:00:00

abstract：INTRODUCTION:Melanoma is one of the most aggressive forms of cutaneous malignancies displaying a substantial mortality rate among the various forms of skin cancers. The management of patients with advanced melanoma poses a significant challenge considering that the disease is refractory to most conventional therapies. ...

journal_title：Expert opinion on investigational drugs

authors： Bhatia S,Emdad L,Das SK,Hamed H,Dent P,Sarkar D,Fisher PB

更新日期：2014-04-01 00:00:00

abstract：:There is still considerable interest in cephem antibacterial agents. In fact, there are a significant number of patents submitted for this antibacterial class. All the new cephem derivatives, independent of which group they belong to (III to V), possess a 2-amino-5-thiazolyl or a 5-amino-2-thiadiazolyl ring with an ox...

journal_title：Expert opinion on investigational drugs

authors： Bryskier A

更新日期：1997-03-01 00:00:00

abstract：:Asthma is a serious world health problem characterised by a chronic inflammatory disorder of the airways. Asthma attacks, or exacerbations, are episodic but airway inflammation is chronically present. Thus, this disorder requires long-term management. The goals of asthma management include prevention steps for long-te...

journal_title：Expert opinion on investigational drugs

authors： Centanni S,Santus P

更新日期：2002-01-01 00:00:00

abstract：INTRODUCTION:Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in th...

journal_title：Expert opinion on investigational drugs

authors： Folli F,Guardado Mendoza R

更新日期：2011-12-01 00:00:00

abstract：INTRODUCTION:Glioblastoma is a primary brain tumor with a poor prognosis despite multimodal therapy including surgery, radiotherapy and alkylating chemotherapy. Novel therapeutic options are therefore urgently needed; however, there have been various drug failures in late-stage clinical development. The proteasome repr...

journal_title：Expert opinion on investigational drugs

authors： Roth P,Mason WP,Richardson PG,Weller M

更新日期：2020-10-01 00:00:00

abstract：:Neuroimmunophilin ligands are a class of compounds that hold great promise for the treatment of nerve injuries and neurological disease. In contrast to neurotrophins (e.g., nerve growth factor), these compounds readily cross the blood-brain barrier, being orally effective in a variety of animal models of ischaemia, tr...

journal_title：Expert opinion on investigational drugs

authors： Gold BG

更新日期：2000-10-01 00:00:00

abstract：:Colorectal cancer is one of the most common cancers worldwide. Through well-designed clinical trials, advances have been made in the treatment of localised and advanced colorectal cancer. It has been established that 6 months of 5-fluorouracil-based chemotherapy will improve overall survival in patients with stage III...

journal_title：Expert opinion on investigational drugs

authors： Mulcahy MF,Benson AB 3rd

更新日期：2002-06-01 00:00:00

abstract：:Since the introduction of the first through the skin (TTS) therapeutic in 1980, a total of 34 TTS products have been marketed and numerous drugs have been tested by more than 50 commercial organisations for their suitability for TTS delivery. Most of the agents which have been tested have had low molecular weights, du...

journal_title：Expert opinion on investigational drugs

authors： Cevc G

更新日期：1997-12-01 00:00:00

abstract：:Overactive bladder (OAB) is a chronic distressing condition characterised by urinary urgency with or without urge incontinence, usually with frequency (voiding at least eight times daily) and nocturia. It affects millions of people worldwide independent of age, sex and race. The prevalence increases with age and is re...

journal_title：Expert opinion on investigational drugs

authors： Tiwari A,Naruganahalli KS

更新日期：2006-09-01 00:00:00

abstract：INTRODUCTION:In 2010, about 8.8 million new cases of tuberculosis were recorded and 1.1 million people died of tuberculosis worldwide. Although numbers are in decrease since 2006, tuberculosis still represents a global issue and a major public health threat, due to appearance of multidrug-resistant and extensively drug...

journal_title：Expert opinion on investigational drugs

authors： Engohang-Ndong J

更新日期：2012-12-01 00:00:00

abstract：:Numerous studies over the last few years have suggested that modulating the glutamatergic system may be an efficient method to achieve an antidepressant effect. Data suggest that metabotropic glutamate receptors (mGlu receptors), related to long-term, modulatory effects on glutamatergic neurotransmission, may be a goo...

journal_title：Expert opinion on investigational drugs

authors： Palucha A

更新日期：2006-12-01 00:00:00

abstract：:Clinical trials showing the benefits of reducing the effects of TNF- alpha in rheumatoid arthritis have highlighted the key role of the cytokine TNF- alpha in this inflammatory condition. A new approach to reducing the effects of TNF- alpha is to decrease its synthesis by inhibiting TNF- alpha converting enzyme with G...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2002-07-01 00:00:00

abstract：INTRODUCTION:Posttraumatic stress disorder (PTSD) is a prevalent, chronic and disabling anxiety disorder that may develop following exposure to a traumatic event. There is currently no effective pharmacotherapy for PTSD and therefore the discovery of novel, evidence-based treatments is particularly important. This revi...

journal_title：Expert opinion on investigational drugs

authors： Ragen BJ,Seidel J,Chollak C,Pietrzak RH,Neumeister A

更新日期：2015-05-01 00:00:00

abstract：:There is a growing understanding of the central role that platelets play in coronary artery disease. The glycoprotein IIb/IIIa receptor has recently been identified as the final common pathway for platelet aggregation and hence has been the focus of many clinical trials to influence various aspects of coronary artery ...

journal_title：Expert opinion on investigational drugs

authors： Salam AM,Suwaidi JA

更新日期：2002-11-01 00:00:00

abstract：:'Male factor' problems contribute to subfertility in a significant proportion of couples. In some instances, defective sperm production has qualitative and/or quantitative effects on the semen profile; in others, no obvious defects can be detected, yet spermatozoa are non-fertilising. Recent studies have revealed that...

journal_title：Expert opinion on investigational drugs

authors： Fraser LR

更新日期：1997-12-01 00:00:00

abstract：BACKGROUND:Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs. OBJECTIVE:This review will examine a novel AAD, tedisamil--a multichannel potassium c...

journal_title：Expert opinion on investigational drugs

authors： Krishnamoorthy S,Lip GY

更新日期：2009-08-01 00:00:00

abstract：:Control of the immune system is of indispensable importance for graft acceptance and function. Immunological changes in the graft before and after organ harvesting, the transplantation procedure itself and the organ recipients clinical state contribute to the immune response. Leukocyte trafficking [1] into a graft is ...

journal_title：Expert opinion on investigational drugs

authors： Behrend M

更新日期：2000-04-01 00:00:00

abstract：:In most countries the last two decades have seen a very substantial rise in the prevalence of heart failure, and in a majority of patients hypertension is both an antecedent condition and a contributing cause. Heart failure is also a major cause of hospital admissions; its amelioration and, as far as possible, prevent...

journal_title：Expert opinion on investigational drugs

authors： Funder JW

更新日期：2003-12-01 00:00:00

abstract：INTRODUCTION:Dyslipidemia is one of the most important risk factors for cardiovascular disease. Insufficient reduction in LDL-C from existing therapies in patients at high risk of atherogenic cardiovascular disease is an unmet clinical need. Circulating PCSK9 causes hypercholesterolemia by reducing LDL receptors in hep...

journal_title：Expert opinion on investigational drugs

authors： Nishikido T,Ray KK

更新日期：2018-03-01 00:00:00

abstract：:The interaction between the urokinase receptor (uPAR) and its ligand urokinase (uPA) mediates phenomena such as tissue remodelling, chemotaxis, tumour invasion, dissemination, proliferation, and angiogenesis. The broad-spectrum of biological processes that the uPA/uPAR interaction plays a role in has led researchers t...

journal_title：Expert opinion on investigational drugs

authors： Weidle UH,König B

更新日期：1998-03-01 00:00:00

abstract：:With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

journal_title：Expert opinion on investigational drugs

authors： Schultze JL

更新日期：1999-12-01 00:00:00